Table 1.
Baseline and procedural characteristics for patients in the main development cohort
| Variable* | Summary (n=6339) | Missing (% of 6339) |
| Age, mean (range) | 81.25 (29–101) | 0 (0) |
| Female, n (%) | 2927 (46.17) | 22 (0.35) |
| Non-Caucasian, n (%) | 249 (3.93) | 65 (1.03) |
| Diabetic, n (%) | 1463 (23.08) | 35 (0.55) |
| Current or ex-smoker, n (%) | 3240 (51.11) | 245 (3.86) |
| Height (m), mean (range) | 1.65 (1.10–2.36) | 156 (2.46) |
| Weight (kg), mean (range) | 74.23 (32–190) | 129 (2.04) |
| Creatinine, µmol/L, mean (range) | 114.2 (29–1044) | 71 (1.12) |
| Dialysis, n (%) | 122 (1.92) | 66 (1.04) |
| MI within 30 days of TAVI, n (%) | 60 (0.95) | 33 (0.52) |
| Pulmonary disease, n (%) | 1777 (28.03) | 87 (1.37) |
| Cerebrovascular disease, n (%) | 913 (14.40) | 34 (0.54) |
| Extracardiac arteriopathy, n (%) | 1462 (23.06) | 84 (1.33) |
| Calcified aorta, n (%) | 1076 (16.97) | 73 (1.15) |
| Sinus rhythm, n (%) | 4054 (63.95) | 106 (1.67) |
| Previous cardiac surgery, n (%) | 1990 (31.39) | 35 (0.55) |
| Prior BAV, n (%) | 694 (10.95) | 32 (0.50) |
| Previous PCI, n (%) | 1272 (20.07) | 34 (0.54) |
| Critical preoperative state, n (%) | 98 (1.55) | 81 (1.28) |
| NYHA class IV, n (%) | 1089 (17.18) | 42 (0.66) |
| Poor mobility, n (%) | 662 (10.44) | 3423 (54.00) |
| CSHA frail, n (%) | 1165 (18.38) | 3419 (53.94) |
| KATZ<6, n (%) | 851 (13.42) | 3696 (58.31) |
| PA systolic >60 mm Hg, n (%) | 740 (11.67) | 1816 (28.65) |
| Aortic peak gradient, mean (range) | 74.56 (3.35–200) | 259 (4.09) |
| Aortic valve area, mean (range) | 0.68 (0.2–2) | 388 (6.12) |
| LVEF<50%, n (%) | 2421 (38.19) | 55 (0.87) |
| LMS>50%, n (%) | 275 (4.34) | 138 (2.18) |
| Non-elective procedure, n (%) | 790 (12.46) | 7 (0.11) |
| Non-transfemoral access, n (%) | 1607 (25.35) | 13 (0.21) |
| Valve type | 29 (0.46) | |
| Edwards SAPIEN valve, n (%) | 3553 (56.05) | |
| Medtronic CoreValve, n (%) | 2531 (39.93) | |
| Other, n (%) | 226 (3.57) |
*Variable definitions are given in online supplementary table 1.
BAV, balloon aortic valvuloplasty; CSHA, Canadian Study of Health and Aging; LMS, left main stem disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association Functional Classification; PA, pulmonary artery; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation.